Salspera is targeting Stage IV metastatic pancreatic cancer with Saltikva—an oral, attenuated Salmonella typhimurium engineered to express human IL-2—and plans to put $45M of IPO proceeds into a Phase III trial after completing Phase II testing in metastatic disease. The company has submitted an IND to the FDA as it prepares for pivotal studies, per an SEC filing.

Why It Matters To Oncology

• Pancreatic Cancer (Stage IV PDAC) remains a high-mortality setting where durable immune activation in the tumor microenvironment is a major unmet need.

• Saltikva’s drug-discovery angle is a living, orally delivered immunotherapy designed to locally express IL-2 and stimulate NK cells and CD8+ cytotoxic T cells within tumor microenvironments.

• The approach underscores continued interest in non-traditional platforms (engineered bacteria) to modulate “cold” tumors—alongside cytokines and cell therapies—while potentially shifting exposure toward the tumor site.

The Financials

• IPO terms: ~5.7M shares at $14–$16; midpoint raise: ~$85M.

• Planned use of proceeds: ~$45M for a Phase III study in Stage IV metastatic pancreatic cancer.

• Additional R&D allocation: ~$22M for Phase II trials in osteosarcoma and colorectal cancer.

• Runway: expected proceeds plus existing cash projected to fund operations for at least 12 months and complete planned studies.

What They're Saying

• Salspera describes Saltikva as an oral, attenuated S. typhimurium engineered to express the human IL-2 gene to stimulate immune effector cells in tumor microenvironments.

• The company says it has submitted an IND to the FDA as it moves toward pivotal trials.

What's Next

• FDA feedback on the IND and Phase III trial start timing in Stage IV PDAC.

• Design details to watch: patient selection, backbone regimen/standard-of-care combination, endpoints (OS vs PFS), and safety monitoring for a live biotherapeutic.

• Phase II readouts/initiations in osteosarcoma and colorectal cancer as potential platform validation beyond PDAC.